Oncology and Hematology

Episodes 129-144 of 531

Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Project Oncology®
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
- Kathleen Moore, MD, MS, FASCO
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Project Oncology®
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
- Kathleen Moore, MD, MS
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Project Oncology®
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
- Marlene Mimi Maeusli, PhD.
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Clinician's Roundtable
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
- Ashley Baker, MSN, PMHNP
- Heather Allen, PhD
- Ran Li, PhD
Initiating Colorectal Cancer Screening Earlier: A Look at the Evidence
Initiating Colorectal Cancer Screening Earlier: A Look at the Evidence
Clinician's Roundtable
Initiating Colorectal Cancer Screening Earlier: A Look at the Evidence
- Theodore Levin, MD
Improving Colorectal Cancer Screening Adherence: Advantages of FIT
Improving Colorectal Cancer Screening Adherence: Advantages of FIT
Clinician's Roundtable
Improving Colorectal Cancer Screening Adherence: Advantages of FIT
- Theodore Levin, MD
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Project Oncology®
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
- Ryan Quigley
Boosting Colorectal Cancer Re-Screening: The Role of Spanish Language Navigation
Boosting Colorectal Cancer Re-Screening: The Role of Spanish Language Navigation
Clinician's Roundtable
Boosting Colorectal Cancer Re-Screening: The Role of Spanish Language Navigation
- Ryan Quigley
- Mallik Greene, PhD
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Project Oncology®
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Optimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
Optimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
Project Oncology®
Optimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
- Jacob Sands, MD
- Christine Bestvina, MD
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Clinician's Roundtable
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
- Pedro Nascimento de Lima, PhD
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Project Oncology®
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Project Oncology®
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
- Ryan Quigley
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Project Oncology®
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
- Charles Turck, PharmD, BCPS, BCCCP
- Hope S. Rugo, MD, FASCO
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Project Oncology®
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Project Oncology®
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
- Komal Jhaveri, MD, FACP